0001209191-20-054246.txt : 20201007
0001209191-20-054246.hdr.sgml : 20201007
20201007205907
ACCESSION NUMBER: 0001209191-20-054246
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201005
FILED AS OF DATE: 20201007
DATE AS OF CHANGE: 20201007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Frohlich Tom
CENTRAL INDEX KEY: 0001823925
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 201229963
MAIL ADDRESS:
STREET 1: C/O CHINOOK THERAPEUTICS U.S., INC.
STREET 2: 1600 FAIRVIEW AVE. E.
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADURO BIOTECH, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
BUSINESS PHONE: 510-848-4400
MAIL ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-05
0
0001435049
ADURO BIOTECH, INC.
KDNY
0001823925
Frohlich Tom
C/O CHINOOK THERAPEUTICS, INC.
1600 FAIRVIEW AVE. E.
SEATTLE
WA
98102
0
1
0
0
Chief Business Officer
Common Stock
2020-10-05
4
A
0
153398
A
153398
D
Stock Option (right to buy)
0.42
2020-10-05
4
A
0
98847
A
2030-03-17
Common Stock
98847
98847
D
Stock Option (right to buy)
14.77
2020-10-06
4
A
0
119793
0.00
A
2030-10-05
Common Stock
119793
119793
D
Restricted Stock Units (RSU) (Common Stock)
2020-10-06
4
A
0
40743
0.00
A
2030-10-05
Common Stock
40743
40743
D
Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with the merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer.
The stock option vests as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully
vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Received in connection with the merger of Private Chinook into the Issuer in exchange for a stock option to acquire 338,300
shares of Private Chinook common stock for $0.12 per share.
The stock option vests as to 25% of the total shares on October 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date.
/s/ Kirk Schumacher, Attorney-in-Fact
2020-10-07